Japan Approves Dupixent for Bullous Pemphigoid Treatment

Japan’s Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP), marking an important advancement for patients living with this serious and often debilitating condition.

Bullous pemphigoid is a chronic autoimmune disorder characterized by large, fluid-filled blisters on the skin, which can cause intense itching, discomfort, and an increased risk of infection. The disease primarily affects older adults and often requires long-term treatment, typically involving systemic corticosteroids that can carry significant side effects.

The approval is based on results from the pivotal LIBERTY-BP-ADEPT Phase 2/3 clinical trial, which evaluated Dupixent in adults with moderate-to-severe BP. In the study, patients were randomized to receive either Dupixent 300 mg or a placebo, both in combination with standard-of-care oral corticosteroids. As part of the trial design, corticosteroid doses were gradually reduced when disease control was achieved.

The results demonstrated a clear clinical benefit for Dupixent. At Week 36, 18% of patients treated with Dupixent achieved sustained disease remission, compared to just 4% in the placebo group. This represents more than a fourfold improvement and highlights the therapy’s potential to significantly improve outcomes for patients who often have limited treatment options.

In terms of safety, treatment-related adverse events were reported in 26% of patients receiving Dupixent, compared with 15% in the placebo group. The most commonly reported side effect associated with Dupixent was conjunctivitis, occurring in approximately 4% of treated patients. Overall, the safety profile was considered consistent with previous studies of the drug in other indications.

Dupixent is already approved in Japan for a range of inflammatory conditions, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, prurigo nodularis, chronic spontaneous urticaria, and chronic obstructive pulmonary disease. The latest approval further expands its role as a versatile therapy targeting type 2 inflammation.

This decision provides a new therapeutic option for patients with bullous pemphigoid in Japan, offering the potential for improved disease control and reduced reliance on long-term steroid use.